Every 8-K that Endovia Health Sciences, Inc. (EDVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EDVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDVA filings page.
Endovia Health Sciences, Inc. (EDVA) sold and issued 526,582 shares of common stock to C/M Capital Master Fund, LP on September 30, 2026, for total gross proceeds of $81,830.84 under a Securities Purchase Agreement dated September 19, 2025. To the extent the sales are deemed unregistered, Endovia stated they were made under the exemptions provided by Section 4(a)(2) and Rule 506(b); the purchaser’s resales were registered on a Form S-1 effective August 24, 2026.
Endovia Health Sciences, Inc. (EDVA), alongside Lupvindol BioSciences, announced that the FDA determined the proposed use of CannEpil, an investigational CBD and THC oral solution for pain associated with bone cancer in dogs, qualifies as a “minor use” under MUMS. This makes CannEpil eligible to pursue conditional approval; the FDA said minor-use status will be maintained through approval of the applicable New Animal Drug Application. CannEpil remains investigational and has not been approved or conditionally approved.
Endovia and Lupvindol are scheduled to meet formally with the FDA on November 19, 2026, to discuss the development program, including studies, manufacturing requirements and regulatory submissions. The companies are sourcing and finalizing U.S.-based manufacturing capabilities. A potential veterinary launch in 2027 is subject to regulatory approvals, manufacturing readiness and other factors.
Endovia Health Sciences, Inc. entered into a letter agreement with C/M Capital Master Fund, LP, which committed to invest a minimum of $1 million to support CannEpil regulatory advancement, clinical development planning and commercialization. Endovia closed an initial investment of $510,000 in exchange for a secured convertible note with $576,271 principal, including a $66,271 original issue discount. The note converts at the lower of $1.75 per share or $0.01 above the closing sale price on the conversion date.
The note matures on September 18, 2027, carries no interest except upon default, when interest accrues at 7% per annum, and may be prepaid without premium or penalty. It is also subject to mandatory prepayments of 30% of gross proceeds received from securities issued under the September 19, 2025 equity line of credit facility. From August 31, 2026 through September 23, 2026, Endovia issued 3,629,250 common shares to the investor under that facility for $808,829.42 in gross proceeds.
Endovia Health Sciences, Inc. (EDVA) closed $500,000 of initial secured convertible debt funding from C/M Capital Master Fund, LP, representing the first tranche of a previously announced $1 million investment commitment linked to its exclusive global licensing agreement for the cannabinoid pharmaceutical candidate CannEpil®.
The new capital is intended to support development and commercialization of CannEpil®, including an FDA-regulated veterinary program for management of cancer-related pain in companion animals and international commercialization initiatives. The U.S. FDA Center for Veterinary Medicine has already opened INAD File No. 14145 for CannEpil®, formally starting the investigational veterinary drug process.
Endovia highlights growing federal focus on botanical and plant-derived medicines, citing an FDA initiative on botanical drug development and proposed House bill H.R. 10150, which would grant qualifying botanical drugs approved under Section 505(b)(1) a 12-year market exclusivity period. The company views this policy momentum as supportive of its broader cannabinoid health sciences strategy.
SPLASH BEVERAGE GROUP, INC. (EDVA), now operating as Endovia Health Sciences, reports on U.S. federal moves toward rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act and explains how this supports its cannabinoid-focused strategy.
The company expects to submit a CannEpil® FDA "Z submission" and request a pre-submission conference in the coming week, aiming to advance its proprietary cannabinoid formulation through FDA pathways. It is also reviewing additional cannabinoid-based formulations and IP for potential licensing, acquisition or collaboration, and is working with capital partners to finalize expanded financing to support development and potential transactions. The rebrand to Endovia Health Sciences and ticker EDVA became effective on the NYSE American on August 24, 2026.
SPLASH BEVERAGE GROUP, INC. (symbol EDVA), whose registrant name in this report is Endovia Health Sciences, Inc., reported an unregistered equity financing. On August 25, 2026, the company sold and issued 510,951 shares of common stock to C/M Capital Master Fund, LP under a previously executed Securities Purchase Agreement dated September 19, 2025, generating gross proceeds of $107,610.62.
The shares were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). The purchaser’s resales of these shares are covered by the company’s Form S-1 registration statement (File No. 333-298112), which became effective on August 24, 2026.